

December 4, 2023



# Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 2:30 p.m. ET / 11:30 a.m. PT.

A webcast of the fireside chat will be accessible through the News & Events page of the Investor Relations section of the company's website at [www.sutro.bio.com](http://www.sutro.bio.com). An archived replay will be available for at least 30 days after the event.

## About Sutro Biopharma

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro's fit-for-purpose technology, including cell-free XpressCF<sup>®</sup>, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolR $\alpha$ )-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro's continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @SutroBio, or visit [www.sutro.bio.com](http://www.sutro.bio.com).

## Contact

Emily White  
Sutro Biopharma  
(650) 823-7681  
[ewhite@sutro.bio.com](mailto:ewhite@sutro.bio.com)



Source: Sutro Biopharma, Inc.